In general, patients with early cardiac hypertrophy can survive for several years to decades with strict treatment, and may even have no significant impact on the patient’s life expectancy; patients with severe end-stage have a shorter survival period. Cardiac hypertrophy belongs to ventricular remodeling, is a compensatory manifestation of heart failure patients, according to the pathological characteristics of the cardiac hypertrophy and centrifugal hypertrophy. Cardiac hypertrophy is a relatively early stage, which can be slowed down by angiotensin-converting enzyme inhibitors (e.g., captopril, etc.) and calcium channel antagonists (e.g., nifedipine, amlodipine, etc.), and life expectancy is generally not affected by rigorous treatment. Cardiac hypertrophy is a more advanced stage of compensation, in which patients have obvious symptoms of heart failure and poorer cardiac function, and may experience acute episodes of chronic heart failure under certain triggers, with a decreased survival rate of the patient, and may even experience sudden death. Patients with cardiac hypertrophy must be treated rigorously under the guidance of a physician to alleviate disease progression and prolong survival.